Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 82,572 shares traded hands during mid-day trading, an increase of 26% from the previous session's volume of 65,724 shares.The stock last traded at $9.26 and had previously closed at $9.38.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on TLX. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Wedbush restated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. HC Wainwright cut their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, September 10th. Finally, Citigroup assumed coverage on Telix Pharmaceuticals in a report on Thursday. They set a "buy" rating and a $22.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $21.50.
Get Our Latest Report on Telix Pharmaceuticals
Telix Pharmaceuticals Trading Up 0.7%
The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The business has a fifty day simple moving average of $11.88 and a 200 day simple moving average of $15.10.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the first quarter worth approximately $170,000. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter worth $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals in the 2nd quarter valued at $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $297,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals during the 1st quarter worth $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
